Bader Alahmari

Bader Alahmari

Auto-generated profile, based on publicly available information

Bader Alahmari

Division of Hematology & HSCT, Department of Oncology, King Abdulaziz Medical City, Riyadh, Saudi Arabia

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 October 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
JCJaebok Choi
Jaebok Choi
MCMatthew L Cooper
Matthew L Cooper
BABader Alahmari
Bader Alahmari
JRJulie Ritchey
Julie Ritchey
LCLynne Collins
Lynne Collins
JDJohn F DiPersio
John F DiPersio
We have recently reported that interferon gamma receptor deficient (IFNγR−/−) allogeneic donor T cells result in significantly less graft-versus-host disease (GvHD) than wild-type (WT) T cells, while maintaining an anti-leukemia or graft-versus-leukemia (GvL) effect after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We demonstrated that IFNγR signaling regulates alloreactive T cell trafficking to GvHD target organs through expression of the chemokine receptor CXCR3 in alloreactive T cells. Since IFNγR signaling is mediated via JAK1/JAK2, we tested the effect of JAK1/JAK2 inhibition on GvHD. While we demonstrated that pharmacologic blockade of JAK1/JAK2 in WT T cells using the JAK1/JAK2 inhibitor, INCB018424 (Ruxolitinib), resulted in a similar effect to IFNγR−/− T cells both in vitro (reduction of CXCR3 expression in T cells) and in vivo (mitigation of GvHD after allo-HSCT), it remains to be determined if in vivo administration of INCB018424 will result in preservation of GvL while reducing GvHD. Here, we report that INCB018424 reduces GvHD and preserves the beneficial GvL effect in two different murine MHC-mismatched allo-HSCT models and using two different murine leukemia models (lymphoid leukemia and myeloid leukemia). In addition, prolonged administration of INCB018424 further improves survival after allo-HSCT and is superior to other JAK1/JAK2 inhibitors, such as TG101348 or AZD1480. These data suggest that pharmacologic inhibition of JAK1/JAK2 might be a promising therapeutic approach to achieve the beneficial anti-leukemia effect and overcome HLA-barriers in allo-HSCT. It might also be exploited in other diseases besides GvHD, such as organ transplant rejection, chronic inflammatory diseases and autoimmune diseases.

2 April 2018 in Leukemia
Verified
Journal Article
Closed access
PDF file
JCJaebok Choi
Jaebok Choi
MCMatthew L. Cooper
Matthew L. Cooper
KSKarl Staser
Karl Staser
KAKidist Ashami
Kidist Ashami
KVKiran R. Vij
Kiran R. Vij
JDJohn F DiPersio
John F DiPersio

20 June 2024 in Blood
Verified
Journal Article
Closed access
PDF file
AKAdetola A Kassim
Adetola A Kassim
JFJosu de la Fuente
Josu de la Fuente
ENErfan Nur
Erfan Nur
KWKarina L. Wilkerson
Karina L. Wilkerson
AAAli D. Alahmari
Ali D. Alahmari
MDMichael DeBaun
Michael DeBaun
In the setting of a learning collaborative, we conducted an international multicenter phase 2 clinical trial testing the hypothesis that nonmyeloablative–related haploidentical bone marrow transplant (BMT) with thiotepa and posttransplant cyclophosphamide (PTCy) will result in 2-year event-free survival (no graft failure or death) of at least 80%. A total of 70 participants were evaluable based on the conditioning protocol. Graft failure occurred in 8 of 70 (11.4%) and only in participants aged <18 years; all had autologous reconstitution. After a median follow-up of 2.4 years, the 2-year Kaplan-Meier–based probability of event-free survival was 82.6%. The 2-year overall survival was 94.1%, with no difference between children and adult participants. After excluding participants with graft failure (n = 8), participants with engraftment had median whole blood donor chimerism values at days +180 and +365 after transplant of 100% (n = 58), respectively, and 96.6% (57/59) were off immunosuppression 1 year after transplant. The 1-year grade 3 to 4 acute graft-versus-host disease (GVHD) rate was 10%, and the 2-year moderate–severe chronic GVHD rate was 10%. Five participants (7.1%) died from infectious complications. We demonstrate that nonmyeloablative haploidentical BMT with thiotepa and PTCy is a readily available curative therapy for most adults, even those with organ damage, compared to the more expensive myeloablative gene therapy and gene editing. Additional strategies are required for children to decrease graft failure rates. The trial was registered at www.clinicaltrials.gov as #NCT01850108.

1 January 2020 in Leukemia Research Reports
Verified
Journal Article
Open access
KAKhadega A Abuelgasim
Khadega A Abuelgasim
BABandar Albuhayri
Bandar Albuhayri
RMRayan Munshi
Rayan Munshi
AMAreej Al Mugairi
Areej Al Mugairi
BABader Alahmari
Bader Alahmari
MDMoussab Damlaj
Moussab Damlaj
The prognosis of acute myeloid leukemia (AML) remains poor. Among 180 patients, the median age was 53 (14-88) years. The overall 2-year disease free survival (DFS) was 28.6% (+/- 3.4), 47.7% (+/- 6.6%) for ≤ 40, 23.6% (+/- 5.8%) for 41-60 and 11.7% (+/- 4.2%) for ≥61 (p< 0.0001). The overall 2-year survival (OS) was 45.3% (+/- 3.8%), 78.6% (+/- 5.5%) for ≤40, 43.5% (+/- 6.9%) for 41-60 and 15.8% (+/- 4.8%) for ≥61 (p< 0.0001). Induction outcome of ≥61 was best in high dose chemotherapy (HDC) group (p < 0.0001). Only those ≤40 had durable DFS and OS. HDC appears to improve the outcome of older AML patients.

27 April 2021 in Bone Marrow Transplantation
Verified
Journal Article
Closed access
PDF file
RFRiad El Fakih
Riad El Fakih
AHAlfadil Haroon
Alfadil Haroon
FAFeras Alfraih
Feras Alfraih
Murtadha Al-KhaboriMurtadha Al-Khabori
Murtadha Al-Khabori
MAMohsen Alzahrani
Mohsen Alzahrani
MAMahmoud Aljurf
Mahmoud Aljurf

30 January 2019 in Bone Marrow Transplantation
Verified
Journal Article
Open access
PDF file
KAKhadega A Abuelgasim
Khadega A Abuelgasim
MAMohsen Alzahrani
Mohsen Alzahrani
YAYousef Alsharhan
Yousef Alsharhan
MKMoataz Khairi
Moataz Khairi
MHMohammed Hommady
Mohammed Hommady
MDMoussab Damlaj
Moussab Damlaj